Loading…
Indian molecular diagnostics company making TrueNat point-of-care PCR testing devices for TB and infectious diseases.
Indian molecular diagnostics company making TrueNat point-of-care PCR testing devices for TB and infectious diseases.
Sells the small battery-run machines and then earns repeatedly on the single-use test chips each sample needs. Government health programmes, including India's TB control, are the biggest buyers and order through tenders, and the World Health Organization's endorsement of its TB test opened many overseas health programmes.
In one line: India's Cepheid equivalent for point-of-care molecular diagnostics.
Moat: narrow (IP / patents, process know-how). Proprietary battery-operated point-of-care PCR platform suited for low-resource settings, unlike lab-bound rivals.
Headquarters: Goa, India · Founded: 2001 · Employees: 2,840
Size Molbio Diagnostics (MOLBIO.NS) is an India Health Care company (Medical Specialties) with a market value of $1.63B, the 430th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹1,339 on 6 Nov 2026.
Growth Revenue grew 35.2% over the last twelve months (peer median +8.8%); the operating margin is 17.3% (peer median 9.7%).
Valuation It trades at 11.7× enterprise value to sales against a peer median of 3.2× (5th most expensive of 21).
Capital Return on invested capital runs 5.7 points above its cost of capital (9.3% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | ₹13.1B | ₹9.71B | ₹8.37B | ₹3.32B |
| Revenue growth | — | +35% | +16% | +152% | — |
| Gross profit | n/a | ₹6.32B | ₹4.49B | ₹3.60B | ₹882M |
| EBITDA | n/a | ₹2.63B | ₹2.35B | ₹2.15B | ₹512M |
| Net income | n/a | ₹1.45B | ₹1.40B | ₹1.02B | -₹7.26M |
| Free cash flow | n/a | -₹899M | ₹2.04B | -₹170M | ₹476M |
| Capital expenditure | n/a | ₹361M | ₹422M | ₹161M | ₹145M |
| Total debt | n/a | ₹3.46B | ₹262M | ₹1.84B | ₹1.19B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Molbio Diagnostics MOLBIO.NS | $1.63B | n/a | +35% | 17% | 11.7× | n/a |
| Danaher DHR | $162B | +35% | +6% | 21% | 7.2× | 20.5% |
| Abbott Laboratories ABT | $190B | +30% | +10% | 14% | 3.9× | 5.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MOLBIO.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.3% | +2.5% | 5th lowest of 21 |
| Distance from 52-week high | -20.6% | -21.2% | 8th highest of 21 |
| Revenue growth (TTM) | +35.2% | +8.8% | 5th highest of 21 |
| Operating margin | 17.3% | 9.7% | 6th highest of 21 |
| EV / Sales | 11.7× | 3.2× | 5th most expensive of 21 |
| ROIC minus cost of capital | +5.7 pp | -1.7 pp | 6th highest of 21 |
| EV / EBITDA | 58.6× | 15.8× | most expensive of 12 |
| Net debt / EBITDA | 0.9× | 2.0× | 6th least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Molbio Diagnostics MOLBIO.NS | India | $1.63B | n/a | +35% | 17% | 11.7× | n/a | n/a |
| Vitrolife VITR.ST | Sweden | $1.63B | +14% | -2% | 19% | 4.9× | 22.0% | +22.5% |
| Nihon Kohden 6849.T | Japan | $1.63B | +8% | +1% | 7% | 1.0× | -2.1% | +3.3% |
| Rigaku 268A.T | Japan | $1.66B | -57% | +5% | 15% | 3.2× | 18.8% | +14.5% |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.59B | -14% | +16% | 44% | 5.9× | 3.1% | +23.4% |
| Sinocare 300298.SZ | China | $1.58B | +15% | +7% | 6% | 2.1× | 10.8% | +18.3% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.69B | +124% | +3% | 49% | 21.4× | 17.9% | +12.7% |
| Enovis ENOV | United States | $1.57B | +2% | +5% | 3% | 1.3× | 22.3% | -6.0% |
| Butterfly Network BFLY | United States | $1.70B | +53% | +39% | -36% | 13.0× | n/a | n/a |
| Cofoe Medical Technology 301087.SZ | China | $1.71B | -5% | +33% | 10% | 2.3× | 12.5% | +7.4% |
| NIPRO 8086.T | Japan | $1.55B | -9% | +3% | 6% | 1.3× | n/a | n/a |
| NovoCure NVCR | United States | $1.55B | -26% | +13% | -17% | 1.8× | n/a | n/a |
| Kestra Medical Technologies KMTS | United States | $1.72B | +37% | +61% | -134% | 14.9× | n/a | n/a |
| Poly Medicure POLYMED.NS | India | $1.73B | -4% | +18% | 17% | 8.2× | n/a | n/a |
| CONMED CNMD | United States | $1.53B | +40% | +2% | 2% | 1.7× | 32.4% | +9.8% |
| Angelalign Technology 6699.HK | Hong Kong | $1.74B | -7% | +84% | 9% | 3.2× | 18.1% | +25.8% |
| Embla Medical hf EMBLA.CO | Denmark | $1.75B | +3% | +6% | 14% | 2.2× | -1.8% | +8.3% |
| Fukuda Denshi 6960.T | Japan | $1.75B | -5% | 0% | 19% | 1.5× | -3.2% | -1.0% |
| Wuxi Unicomp Technology 688531.SS | China | $1.80B | -36% | +53% | 12% | 7.9× | n/a | n/a |
| Beijing Balance Medical Technology 688198.SS | China | $1.47B | -26% | +10% | 28% | 15.0× | 22.6% | +27.6% |
| Medartis MED.SW | Switzerland | $1.83B | +47% | +30% | 2% | 5.5× | n/a | n/a |